Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune Encephalitis and Epilepsy Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LGI1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LGI1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View LGI1 Products |
| Gene Delivery | LGI1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View LGI1 Products |
| Benchmark Ab | Anti-LGI1 (Sequence of clinical-grade positive control) Recombinant positive control. |
View LGI1 Products |
| Validator | LGI1 siRNA Set For knockdown verification. |
View LGI1 Products |
| Related Target A | ADAM22 Postsynaptic receptor for LGI1; critical for validating LGI1-ADAM22 interaction inhibition. |
View ADAM22 Products |
| Related Target B | ADAM23 Presynaptic receptor for LGI1; essential for mapping trans-synaptic complex assembly. |
View ADAM23 Products |
| Related Target C | KCNA1 Kv1.1 voltage-gated potassium channel, downstream effector of the LGI1-ADAM complex. |
View KCNA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation-dependent autoantibody binding | HEK293 Expressed (Native Glycosylation) to preserve authentic tertiary structure |
| High-throughput Cell-Based Assay (CBA) setup | High-titer Lentivirus Premade Particles for stable, uniform LGI1 cell surface expression |
| Lack of standardized positive controls | Recombinant Clinical Benchmark Antibodies included in the catalog |
| Subfamily cross-reactivity (LGI2/3/4 off-target screening) | Sequence-verified LGI family homolog proteins strictly verified by mass spectrometry |
Live LGI1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LGI1 therapeutics is intensifying, with major players shifting focus from traditional global immunosuppression to antigen-specific precision therapies and high-sensitivity diagnostics. As first-generation diagnostic cell-based assays (CBAs) become standard in clinical neurology, the next wave of R&D is targeting autoimmune encephalitis with decoy receptors, selective blockades, and CAR-T/CAAR-T cell therapies designed to deplete anti-LGI1 B-cell populations.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Cell-Based Diagnostics (CBA) | Euroimmun, Athena Diagnostics, Academic Medical Centers | Autoimmune Encephalitis, Faciobrachial Dystonic Seizures (FBDS) | Stable cell lines expressing native LGI1 (Need Lentivirus for Stable Cell Line) |
| Antigen-Specific CAAR-T / Tolerogenic Therapies | Biotech Startups, Academic Research Institutes | LGI1-Antibody Encephalitis | Binding specificity assays (Need high-purity LGI1 ECD-Fc and ADAM22/23 proteins) |
| Small Molecule / Peptide Modulators | Neuroscience-focused Biopharma | Epilepsy (ADLTE), Cognitive Disorders | Protein-protein interaction (PPI) inhibition assays (Need LGI1-ADAM22 binding validation) |